1.

DataSheet1_Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care.PDF

2.

DataSheet1_Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care.PDF

3.

DataSheet1_Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care.PDF

4.

DataSheet1_Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care.PDF

5.

DataSheet1_Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care.PDF

6.

DataSheet1_Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care.PDF

7.

DataSheet1_Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care.PDF

8.

DataSheet1_Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care.PDF

9.

DataSheet1_Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care.PDF

1.

datasheet1_Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis.docx

2.

datasheet1_Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis.docx

3.

datasheet1_Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis.docx

4.

datasheet1_Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis.docx

5.

datasheet1_Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis.docx

6.

datasheet1_Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis.docx

7.

datasheet1_Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis.docx

8.

datasheet1_Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis.docx

9.

datasheet1_Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis.docx

1.

table1_Differences in Importance Attached to Drug Effects Between Patients With Type 2 Diabetes From the Netherlands and Turkey: A Preference Study.pdf

2.

table1_Differences in Importance Attached to Drug Effects Between Patients With Type 2 Diabetes From the Netherlands and Turkey: A Preference Study.pdf

3.

table1_Differences in Importance Attached to Drug Effects Between Patients With Type 2 Diabetes From the Netherlands and Turkey: A Preference Study.pdf

4.

table1_Differences in Importance Attached to Drug Effects Between Patients With Type 2 Diabetes From the Netherlands and Turkey: A Preference Study.pdf

5.

table1_Differences in Importance Attached to Drug Effects Between Patients With Type 2 Diabetes From the Netherlands and Turkey: A Preference Study.pdf

1.

table2_Differences in Importance Attached to Drug Effects Between Patients With Type 2 Diabetes From the Netherlands and Turkey: A Preference Study.pdf

2.

table2_Differences in Importance Attached to Drug Effects Between Patients With Type 2 Diabetes From the Netherlands and Turkey: A Preference Study.pdf

3.

table2_Differences in Importance Attached to Drug Effects Between Patients With Type 2 Diabetes From the Netherlands and Turkey: A Preference Study.pdf

4.

table2_Differences in Importance Attached to Drug Effects Between Patients With Type 2 Diabetes From the Netherlands and Turkey: A Preference Study.pdf

5.

table2_Differences in Importance Attached to Drug Effects Between Patients With Type 2 Diabetes From the Netherlands and Turkey: A Preference Study.pdf

1.

table3_Differences in Importance Attached to Drug Effects Between Patients With Type 2 Diabetes From the Netherlands and Turkey: A Preference Study.pdf

2.

table3_Differences in Importance Attached to Drug Effects Between Patients With Type 2 Diabetes From the Netherlands and Turkey: A Preference Study.pdf

3.

table3_Differences in Importance Attached to Drug Effects Between Patients With Type 2 Diabetes From the Netherlands and Turkey: A Preference Study.pdf

4.

table3_Differences in Importance Attached to Drug Effects Between Patients With Type 2 Diabetes From the Netherlands and Turkey: A Preference Study.pdf

5.

table3_Differences in Importance Attached to Drug Effects Between Patients With Type 2 Diabetes From the Netherlands and Turkey: A Preference Study.pdf

1.

DataSheet1_Towards a better detection of patients at-risk of linezolid toxicity in clinical practice: a prospective study in three Belgian hospital centers.PDF

2.

DataSheet1_Towards a better detection of patients at-risk of linezolid toxicity in clinical practice: a prospective study in three Belgian hospital centers.PDF

3.

DataSheet1_Towards a better detection of patients at-risk of linezolid toxicity in clinical practice: a prospective study in three Belgian hospital centers.PDF

4.

DataSheet1_Towards a better detection of patients at-risk of linezolid toxicity in clinical practice: a prospective study in three Belgian hospital centers.PDF

5.

DataSheet1_Towards a better detection of patients at-risk of linezolid toxicity in clinical practice: a prospective study in three Belgian hospital centers.PDF

6.

DataSheet1_Towards a better detection of patients at-risk of linezolid toxicity in clinical practice: a prospective study in three Belgian hospital centers.PDF

7.

DataSheet1_Towards a better detection of patients at-risk of linezolid toxicity in clinical practice: a prospective study in three Belgian hospital centers.PDF

1.

Table1_Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking.DOCX

2.

Table1_Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking.DOCX

1.

table1_Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium.docx

2.

table1_Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium.docx

3.

table1_Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium.docx

4.

table1_Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium.docx

5.

table1_Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium.docx

6.

table1_Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium.docx

7.

table1_Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium.docx

8.

table1_Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium.docx

9.

table1_Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium.docx

1.

Image1_Impact of the 2018 revised Pregnancy Prevention Programme by the European Medicines Agency on the use of oral retinoids in females of childbearing age in Denmark, Italy, Net...

2.

Image1_Impact of the 2018 revised Pregnancy Prevention Programme by the European Medicines Agency on the use of oral retinoids in females of childbearing age in Denmark, Italy, Net...

1.

Image2_Impact of the 2018 revised Pregnancy Prevention Programme by the European Medicines Agency on the use of oral retinoids in females of childbearing age in Denmark, Italy, Net...

2.

Image2_Impact of the 2018 revised Pregnancy Prevention Programme by the European Medicines Agency on the use of oral retinoids in females of childbearing age in Denmark, Italy, Net...